Antiangiogenic plasma activity in patients with systemic sclerosis.

OBJECTIVE Systemic sclerosis (SSc; scleroderma) is a systemic connective tissue disease with an extensive vascular component that includes aberrant microvasculature and impaired wound healing. The aim of this study was to investigate the presence of antiangiogenic factors in patients with SSc. METHODS Plasma samples were obtained from 30 patients with SSc and from 10 control patients without SSc. The samples were analyzed for the ability of plasma to affect endothelial cell migration and vascular structure formation and for the presence of antiangiogenic activity. RESULTS Exposure of normal human microvascular dermal endothelial cells to plasma from patients with SSc resulted in decreased cell migration (mean +/- SEM 52 +/- 5%) and tube formation (34 +/- 6%) compared with that in plasma from control patients (P < 0.001 for both). SSc plasma contained 2.9-fold more plasminogen kringle 1-3 fragments (angiostatin) than that in control plasma. The addition of angiostatin to control plasma resulted in inhibition of endothelial cell migration and proliferation similar to that observed in SSc plasma. In vitro studies demonstrated that granzyme B and other proteases contained in T cell granule content cleave plasminogen and plasmin into angiostatin fragments. CONCLUSION Plasminogen conformation in patients with SSc enables granzyme B and granule content protease to limit the proangiogenic effects of plasmin and increase the levels of antiangiogenic angiostatin. This increase in angiostatin production may account for some of the vascular defects observed in patients with SSc.

[1]  M. Simons,et al.  Current concepts in normal and defective angiogenesis: Implications for systemic sclerosis , 2007, Current rheumatology reports.

[2]  R Porcher,et al.  Skin involvement in scleroderma--where histological and clinical scores meet. , 2007, Rheumatology.

[3]  M. Simons,et al.  The Anti-angiogenic Activity of rPAI-123 Inhibits Fibroblast Growth Factor-2 Functions* , 2006, Journal of Biological Chemistry.

[4]  B. Giusti,et al.  A model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients , 2006, Arthritis research & therapy.

[5]  E. P. Kay,et al.  Cross-talk among Rho GTPases acting downstream of PI 3-kinase induces mesenchymal transformation of corneal endothelial cells mediated by FGF-2. , 2006, Investigative ophthalmology & visual science.

[6]  A. Zalewska,et al.  Correlation of Endostatin and Tissue Inhibitor of Metalloproteinases 2 (TIMP2) Serum Levels With Cardiovascular Involvement in Systemic Sclerosis Patients , 2005, Mediators of inflammation.

[7]  C. Lewis,et al.  Angiogenesis inhibitors found within the haemostasis pathway , 2005, Journal of cellular and molecular medicine.

[8]  M. Simons.  Angiogenesis: where do we stand now? , 2005, Circulation.

[9]  M. Jinnin,et al.  Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. , 2005, The Journal of investigative dermatology.

[10]  A. Vaheri,et al.  Regulation and interactions in the activation of cell-associated plasminogen , 2004, Cellular and Molecular Life Sciences CMLS.

[11]  Y. Ikeda,et al.  Defective vasculogenesis in systemic sclerosis , 2004, The Lancet.

[12]  J. Folkman.  Endogenous angiogenesis inhibitors , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[13]  H. Ihn,et al.  Increased Expression Levels of Integrin αvβ5 on Scleroderma Fibroblasts , 2004 .

[14]  G. Soff,et al.  Cell Surface-Dependent Generation of Angiostatin4.5 , 2004, Cancer Research.

[15]  Y. Konttinen,et al.  Vascular damage and lack of angiogenesis in systemic sclerosis skin , 2003, Clinical Rheumatology.

[16]  A. Gelber,et al.  Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. , 2003, Arthritis and rheumatism.

[17]  M. Conforti,et al.  Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.

[18]  A. Gelber,et al.  Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. , 2002, Arthritis and rheumatism.

[19]  Michael Simons,et al.  Fibroblast growth factor–specific modulation of cellular response by syndecan-4 , 2002, The Journal of cell biology.

[20]  P. Goldschmidt-Clermont,et al.  Deficient Smad7 expression: A putative molecular defect in scleroderma , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Kahn,et al.  Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.

[22]  M. Idzko,et al.  The role of the urokinase‐type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis , 2001, Journal of cutaneous pathology.

[23]  M. Pepper.  Role of the Matrix Metalloproteinase and Plasminogen Activator-Plasmin Systems in Angiogenesis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[24]  M. Wahl,et al.  Effects of microenvironmental extracellular pH and extracellular matrix proteins on angiostatin's activity and on intracellular pH. , 2000, General pharmacology.

[25]  T. Sasaki,et al.  Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. , 2000, Journal of molecular biology.

[26]  M. Simons,et al.  Synectin, syndecan‐4 cytoplasmic domain binding PDZ protein, inhibits cell migration , 2000, Journal of cellular physiology.

[27]  L. Hornez,et al.  Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[28]  A. Trifiletti,et al.  Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon. , 2000, Panminerva Medica (Testo stampato).

[29]  J. Folkman,et al.  Regulation of Angiostatin Production by Matrix Metalloproteinase-2 in a Model of Concomitant Resistance* , 1999, The Journal of Biological Chemistry.

[30]  A. Rosen,et al.  Cleavage by Granzyme B Is Strongly Predictive of Autoantigen Status , 1999, The Journal of experimental medicine.

[31]  V. Sukhatme,et al.  Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. , 1999, Biochemical and biophysical research communications.

[32]  H. Wu,et al.  Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Hogg,et al.  Angiostatin Formation Involves Disulfide Bond Reduction and Proteolysis in Kringle 5 of Plasmin* , 1999, The Journal of Biological Chemistry.

[34]  C. Ponting,et al.  Evidence that the conformation of unliganded human plasminogen is maintained via an intramolecular interaction between the lysine-binding site of kringle 5 and the N-terminal peptide. , 1998, The Biochemical journal.

[35]  N. Thornberry,et al.  Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. , 1998, Immunity.

[36]  H. Lijnen,et al.  Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). , 1998, Biochemistry.

[37]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[38]  K. Morgan,et al.  Requirement for Protein Kinase C θ for Cell Cycle Progression and Formation of Actin Stress Fibers and Filopodia in Vascular Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[39]  P. Hogg,et al.  Generation of Angiostatin by Reduction and Proteolysis of Plasmin , 1997, The Journal of Biological Chemistry.

[40]  J. Folkman,et al.  Kringle Domains of Human Angiostatin , 1996, The Journal of Biological Chemistry.

[41]  N. Flavahan,et al.  Raynaud's phenomenon. , 1996, Rheumatic diseases clinics of North America.

[42]  E. Leroy.  SYSTEMIC SCLEROSIS : A Vascular Perspective , 1996 .

[43]  A. Blann,et al.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. , 1996, Annals of the rheumatic diseases.

[44]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[45]  A. Koch,et al.  Decreased monocyte-mediated angiogenesis in scleroderma. , 1992, Clinical Immunology and Immunopathology.

[46]  E. Skopińska-Różewska,et al.  Modulatory effect of sera from scleroderma patients on lymphocyte-induced angiogenesis. , 1985, Arthritis and rheumatism.

[47]  S. Schwartz,et al.  Organization of actin cytoskeleton during early endothelial regeneration in vitro. , 1984, Journal of cell science.

[48]  Leroy Ec,et al.  Endothelial injury in scleroderma. A protease mechanism. , 1983 .

[49]  M. Hoylaerts,et al.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. , 1982, The Journal of biological chemistry.

[50]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[51]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[52]  M. Kahaleh,et al.  Endothelial injury in scleroderma , 1979, The Journal of experimental medicine.

[53]  R. Behringer,et al.  Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. , 2007, Arthritis and rheumatism.

[54]  Livia Casciola-Rosen,et al.  Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: insights into the association of specific autoantibodies with distinct disease phenotypes. , 2004, Arthritis and rheumatism.

[55]  J. Ware,et al.  Therapeutic angiogenesis in cardiovascular disease , 2003, Nature Reviews Drug Discovery.

[56]  M. Wahl,et al.  Angiostatin induces intracellular acidosis and anoikis in endothelial cells at a tumor-like low pH. , 2002, Endothelium : journal of endothelial cell research.

[57]  H. Ihn.  The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. , 2002, Archivum immunologiae et therapiae experimentalis.

[58]  V. Linde,et al.  Elimination of the Cys558-Cys566 bond in Lys78-plasminogen--effect on activation and fibrin interaction. , 1998, European journal of biochemistry.

[59]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.